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Abstract: Repeated blood donors manifest clinical, subclinical, and biochemical signs of iron 
deficiency anemia, have significantly higher erythropoietin and vascular endothelial growth 
factor (VEGF) concentrations, and decreased tissue oxygen saturation, oxygenated tissue 
hemoglobin, and regional cerebral oxygen saturation. Erythropoietin and VEGF are potent 
retinal angiogenic factors which may initiate and promote the retinal angiogenesis process 
independently or simultaneously. Increases in circulating levels of erythropoietin and VEGF 
are proportionate to the levels of hematocrit, hypoxemia, and tissue hypoxia. It is suggested that 
higher erythropoietin production following iron deficiency anemia-induced chronic hypoxemia/
hypoxia may, hypothetically, enhance the risk of retinal angiogenesis and/or neovascularization, 
possibly by inducing hypoxia inducible factor-1 alpha, which consequently upregulates genes 
stimulating angiogenesis, resulting in formation of a new vasculature, possibly by modulation 
of signal transducer and activator of transcription 3 signaling in the retina. Implications of this 
hypothesis cover erythropoietin doping, chronic hypoxia, and hypoxemic situations, such as 
angiogenesis-related cardiac and pulmonary diseases.
Keywords: repeated blood donation, erythropoietin, retinal neovascularization, vascular 
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Introduction
The need for blood products is constant and unremitting.1 Only a small percentage 
of eligible individuals answer the appeal to donate. However, there is a subgroup of 
people who donate blood repeatedly. High demand for blood may have led to a bias 
towards investigations analyzing and reporting beneficial effects of blood donation, 
such as reduced risk of myocardial infarction,2,3 improved rheological properties,4,5 and 
blood lipid-lowering effects.6 Overstressing any beneficial health effect might trigger 
the eagerness of blood donors, especially considering the fact that in some countries 
these people are appreciated in many ways (for example, being shown on television). 
This may spark an extreme desire to donate blood repeatedly among multitime donors. 
Also, blood donors might be categorized to include healthy people and ill people who, 
for whatever reason, think they should or have been advised to donate blood. For 
example, there is a widespread belief that blood donation improves blood coagulation 
in diabetics and in smokers. While these ideas might be true, this should not lead to a 
situation where the decision to donate blood becomes obsessive.
It would not be surprising if a disease with low prevalence but high severity, such 
as retinal angiogenesis and/or retinal neovascularization, was underdiagnosed in a 
very small group of repeated blood donors if there were no structured items included 
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in a donor medical questionnaire, or if ophthalmological 
observations are not considered when providing preliminary 
data to be analyzed prospectively or retrospectively. Impor-
tantly, this is likely to happen because there is currently no 
hypothesis proposing a link between them.
To the best of the author’s knowledge, any detrimen-
tal effects of repeated blood donation on erythropoiesis 
counterbalance the risk of induced retinal hypoxia, and its 
subsequent possible effects on retinal angiogenesis and/or 
retinal neovascularization in humans have been overlooked 
to date. This review suggests that repeated blood donors 
might be physiologically at increased risk of ocular altera-
tions. This personal view may have relevant applications 
in other angiogenesis-related disorders. If this theory is 
proven, a simple and inexpensive prophylactic measure can 
be provided for multitime blood donors. Also, eligibility 
and deferral criteria for this special group should be revis-
ited if proven. An extensive search for evidence concerning 
a possible relationship between repeated blood donation 
and retinal alteration included the CENTRAL, MEDLINE, 
EMBASE, CINAHL, ERIC, Informit, and JST databases, 
as well as gray literature and trial registries from inception 
to May 2011. Key search terms included “  carcinogenesis”, 
“  angiogenesis”, “  vascularization”, “retina”, “blood 
  donation”, “  erythropoietin”, “vascular endothelial growth 
factor”, and “hypoxia inducible factor-1 alpha”.
Erythropoietin, blood donation,  
and the retina
The discovery that erythropoietin and its receptor play a sig-
nificant biological role in tissues outside of the hematopoietic 
system has fueled significant interest in erythropoietin as a 
novel cytoprotective agent in both neuronal and vascular 
systems.7 In addition to the kidney, which is the main site of 
production in the adult, additional organs and cells, includ-
ing the liver, uterus, endothelial cells, vascular smooth 
muscle cells, and insulin-producing cells have been found 
to secrete erythropoietin.7,8 The erythropoietin receptor 
(EPOR) is expressed by a variety of cells, including neurons, 
microglia, astrocytes, and cerebral endothelial cells, myelin 
sheaths on human peripheral nerves, and the neural retina 
of the eye.9–11
EPOR is a member of the type 1 cytokine recep-
tor family which modulates cell growth, apoptosis, and 
differentiation.12,13 Erythropoietin shows angiogenic activ-
ity in EPOR-expressing vascular endothelial cells, which 
stimulate proliferation, migration, and angiogenesis.14 
Furthermore, EPOR is upregulated in a variety of solid 
malignant neoplasms.13,15 In the pterygium stroma, a variety 
of endothelial cells forming vascular cavities has shown cyto-
plasmic immunoreactivity for EPOR. In normal conjunctival 
epithelium, a few basal cells showed weak homogeneous 
immunoreactivity for EPOR in the cytoplasm. The number 
of EPOR-expressing epithelial cells was much higher in the 
pterygium compared with the normal conjunctiva. EPOR 
expression was marginally detected in stromal microvessels 
of the normal conjunctiva. However, immunoreactivity for 
erythropoietin was not noted in the pterygium epithelium 
and stroma, or in normal conjunctiva, suggesting that the 
erythropoietin-independent EPOR-signaling pathway plays 
a potential role in cell proliferation and angiogenesis in the 
human pterygium.16
In healthy humans, erythropoiesis counterbalances the 
continuous removal of aged red blood cells. Erythropoietin is 
the main growth factor responsible for regulation of red blood 
cell production in steady-state conditions and for enhancing 
the rate of production of red blood cells whenever blood 
loss or hemolysis occurs, and is considered to be the main 
hormone that controls erythropoiesis.17,18 For example, small 
decreases in hematocrit as would be typical after a situation 
such as presurgical autologous blood donation often do not 
result in increased erythropoietin levels or in compensatory 
erythropoiesis.19 However, this might be different in the case 
of repeated blood donation and/or phlebotomy.
The effect of repeated phlebotomy on serum immu-
noreactive erythropoietin levels studied prospectively in 
autologous blood donors has shown an increase in the level 
of serum immunoreactive erythropoietin with successive 
phlebotomies.20 Maeda et al evaluated endogenous serum 
erythropoietin levels in normal subjects after a single 400 mL 
phlebotomy. The subjects were followed up for 56 days. The 
hemoglobin values of both males and females decreased to 
a nadir on days 3–7 post-phlebotomy. Hemoglobin values 
gradually increased, but did not completely recover to pre-
phlebotomy levels by day 56. Serum erythropoietin levels 
increased at six hours post-phlebotomy to 20.1 ± 5.4 mU/mL 
in males and to 20.7 ± 7.0 mU/mL in females from pre-
phlebotomy levels of 14.6 ± 4.0 mU/mL in males and 
13.4 ± 4.1 mU/mL in females, respectively.21
Duda et al studied the effect of exercise performed 
before and 24 hours after withdrawal of 450 mL of blood 
on serum erythropoietin levels in 12 male subjects aged 
23.2 ± 2.6 years with a body mass index of 23.6 ± 2.1 kg/m2 
and VO2 max of 2937 ± 324 mL/min. Withdrawal of 450 mL 
of blood within 24 hours significantly increased the serum 
erythropoietin concentration. The subjects performed an 
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incremental exercise test until exhaustion twice, separated 
by a period of about 7–10 days. The second test was per-
formed 24 hours after withdrawal of 450 mL of blood. In 
the control study, no effect of incremental exercise on serum 
erythropoietin concentration was seen, which amounted to 
14.24 ± 7.66 mU/mL at rest and 14.97 ± 6.07 mU/mL at the 
end of the incremental test. During the experiment performed 
24 hours after withdrawal of 450 mL of blood, the serum 
erythropoietin concentration at rest was significantly elevated 
(P , 0.01) in relation to the control measurement (  amounting 
to 24.85 ± 13.60 mU/mL) and, at the end of incremental 
exercise, a tendency towards further elevation (P = 0.09) in 
erythropoietin concentration up to 28.32 ± 14.51 mU/mL 
was observed.22
In another study, Bofill et al investigated whether the 
presence of type 2 diabetes mellitus influences the eryth-
ropoietin response to repeated phlebotomies in normal 
subjects. Subjects were aged 43–79 years, with a mean age 
of 64.8 ± 8.8 years in diabetic patients and 65.0 ± 6.1 years 
in controls. As a group, the diabetic patients donated a mean 
of 2.71 ± 0.70 (range 1–4) blood units and control patients 
donated a mean of 3.14 ± 0.65 (range 2–5) blood units. 
These differences were statistically significant (P , 0.05), 
representing 12.1% less blood being predonated in diabetic 
patients. Serum erythropoietin levels in controls increased 
uniformly between 1.5-fold and 3.2-fold from initial values, 
but changes in diabetic patients ranged from no increase in 
four patients to a 12-fold increase in one patient.23
Higher whole blood and plasma viscosity has been cor-
related with several ocular disorders, including age-related 
macular degeneration,24,25 retinal vein thrombosis,26 and 
retinal neovascularization.24,26,27 In a study by Meada et al,21 
erythropoietin levels after a single 400 mL phlebotomy 
continued to increase to peak levels of 25.5 ± 6.3 mU/mL 
in males and 28.7 ± 11.5 mU/mL in females on days 7–14 
and thereafter decreased until day 56.
What does this observation suggest? Although blood 
donation has been shown to reduce viscosity,28 it is possible 
that successive blood donations chronically increase eryth-
ropoietin levels and upregulate EPOR. Although it is usually 
considered that blood donation improves blood viscosity, 
this might be an immediate effect, and longitudinal data are 
needed to compare single versus repeated blood donation. 
However, considering the enhancing effect of blood donation 
on serum erythropoietin until day 56, it is possible that blood 
viscosity might actually be increased in the long term, and 
thus interactions with different severity in different people in 
different physiologic or pathologic situations would be likely. 
This view by no means negates the possibility that elevated 
erythropoietin might trigger retinal angiogenesis without 
modulating blood viscosity. Trials are warranted to compare 
erythropoietin levels in first-time blood donation versus 
repeated blood donation.
The author knows of no direct evidence of higher EPOR 
expression in repeated blood donors. However, a study in 
children with acute lymphoblastic leukemia showed that 
ectopic expression of ETV6/RUNX1 induced upregulation 
of EPOR. However, anemia did not appear to influence 
EPOR expression on leukemic cells, although children 
with ETV6/RUNX1-positive leukemias had a lower median 
hemoglobin than controls.29 It remains to be elucidated 
whether repeated blood donation upregulates EPOR 
  expression in the human retina.
VEGF, blood donation, and the 
retina
VEGF is expressed in human retina and choroid30 as well as 
sickle cell and choroid,31 and its expression precedes retinal 
neovascularization in the retina and optic nerve.32 VEGF 
mediates tissue hypoxia-induced vasculoangiogenesis, 
hematopoiesis,33 and erythropoiesis.34 Low hemoglobin is 
associated with increased serum levels of VEGF in cancer 
patients,35 and it has been suggested that anemia might 
increase the progression of angiogenesis in malignant and 
benign tumors.35,36
Kawamura et al examined the effect of controlled phle-
botomy on blood flow in an ischemic mouse leg model, in 
which 200 µL of blood were drawn from the tail vein once a 
week. After four weeks, blood flow in the ischemic leg was 
significantly better in the phlebotomy group, and capillary 
density was significantly higher. Repeated phlebotomies 
increased serum erythropoietin levels, as well as expression 
of hypoxia inducible factor-1 alpha (HIF-1α) and VEGF, and 
both expression and activity of Akt and endothelial nitric 
oxide synthase in ischemic legs. Repeated   phlebotomies 
resulted in increased blood flow in ischemic legs via an angio-
genic action that involved the Akt/endothelial nitric oxide 
synthase pathway, endothelial progenitor cell mobilization, 
and their complicated cross-talk.37
Hypoxia/hypoxemia, blood donation, 
and the retina
Iron homeostasis alterations leading to hypoxia has been 
implicated in the regulation of VEGF transcription.38 
Production of VEGF and basic fibroblast growth factor is 
stimulated in hypoxic patients with exacerbated chronic 
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obstructive pulmonary disease, and elevated levels of VEGF 
and basic fibroblast growth factor activate the process of 
neoangiogenesis.39 VEGF and basic fibroblast growth factor 
augment proliferation of retinal pigment epithelium (REP) 
and pericytes, especially under hypoxia, and it has been 
proposed that these two cytokines have a synergistic effect 
at several stages of angiogenesis in the retina.40
Systemic hypoxemia (lung or heart disease) or a vascular 
disease of the retina can cause retinal hypoxia. Oxygen plays 
the key role in stabilizing HIF-1α and its function. When 
the oxygen tension is normal, HIF-1α is rapidly oxidized 
by hydroxylase enzymes, but when cells become hypoxic, 
HIF-1α escapes degradation and starts to accumulate, 
  triggering activation of a large number of genes, including 
VEGF and erythropoietin. HIF-1α has been shown both clini-
cally and experimentally to have a mediating or contributing 
role in several oxygen-dependent retinal diseases, and this 
subject has been reviewed elsewhere.41
Jeger et al investigated whether clinically relevant blood 
loss of 500 mL from healthy volunteers can be detected by 
changes in tissue oxygen saturation after a standardized 
ischemic event. They performed occlusion of the brachial 
artery for three minutes in 20 healthy female blood donors 
before and after blood donation. Tissue oxygen saturation 
and total oxygenated tissue hemoglobin were measured 
continuously at the thenar eminence. Ten healthy volunteers 
were assessed in the same way to examine whether repeated 
vascular occlusion without blood donation exhibits time-
dependent effects. Blood donors had a median age of 30.5 
(range 19–62) years. Their median body mass index was 21 
(range 18–23.5) kg/m2. Median blood volume was estimated 
to be 70 mL/kg body weight or 4060 (range 3500–4550) mL. 
Median capillary hemoglobin was 139 (range 127–157) g/L. 
This was measured once immediately after arrival at the 
blood donation service. In the control group, the median 
age was 23 (range 22–25) years. Median body mass index 
was 21 (range 19–23) kg/m2. Median blood volume was 
4165 (range 3500–4480) mL. Blood donation caused a 
substantial decrease in systolic blood pressure, but did not 
affect resting tissue oxygen saturation and oxygenated tis-
sue hemoglobin values. No changes were seen in the blood 
donor group with regard to the vascular occlusion test, but 
in the control group there was an increase in the oxygenated 
tissue hemoglobin rate of recovery during the reperfusion 
phase. The authors concluded that tissue oxygen saturation 
measured at the thenar eminence is insensitive to blood loss 
of 500 mL, but blood loss greater than this would probably 
lead to   detectable changes.42
Because the retina is a part of the neural system, it 
would be interesting to consider the effect of blood dona-
tion on regional cerebral oxygenation and cerebral blood 
volume. In 50 healthy blood donors who donated 450 mL 
of whole blood within 4–9 minutes, changes in regional 
cerebral   oxygen saturation and cerebral tissue hemoglobin 
concentration were measured. Within the study group, 
regional cerebral oxygen saturation decreased by 0.44% 
(P , 0.01) on average during blood donation, which is still 
within the range of individual physiologic baseline variation. 
The average venous hemoglobin concentration decreased 
significantly by 4.6%, whereas cerebral tissue hemoglobin 
concentration increased significantly by 2.5% and cerebral 
blood volume by 7.%. An increase in cerebral blood volume 
indicates cerebral vasodilation, which seems to be the major 
compensatory mechanism during acute blood loss. The 
decrease in regional cerebral oxygen saturation was relatively 
small, indicating that cerebral oxygenation was maintained 
within the physiologic range.43 However, it is noteworthy 
that a state of anemia and iron deficiency exists in repeated 
blood donors.44,45 Iron deficiency may thus enhance expres-
sion of HIF-1α,46–49 which consequently upregulates genes 
stimulating angiogenesis, resulting in the formation of a new 
vasculature in the retina.50,51
With regard to how hypoxia may be causally related to 
iron deficiency, Smith et al investigated whether increasing or 
decreasing iron availability modifies altitude-induced hypoxic 
pulmonary hypertension. They conducted two randomized, 
double-blind, placebo-controlled trials. In the first one, 
22 healthy men aged 19–60 years resident at sea level were 
studied over one week of hypoxia at an altitude of 4340 m. 
In the second study, 11 men aged 30–59 years resident at 
high altitude and diagnosed with chronic mountain sickness 
were studied over one month of hypoxia at the same altitude. 
In the first protocol, participants received intravenous infu-
sions of Fe(III)-hydroxide sucrose 200 mg or placebo on 
the third day of hypoxia. In the second protocol, patients 
underwent staged isovolemic venesection of 2 L of blood. 
Two weeks later, the patients received intravenous infusions 
of Fe(III)-hydroxide sucrose 400 mg or placebo, which 
were subsequently crossed over. In the sea-level residents, 
approximately 40% of the pulmonary hypertensive response 
to hypoxia was reversed by infusion of iron, which reduced 
pulmonary artery systolic pressure by 6 mmHg (95% con-
fidence interval [CI] 4–8 mmHg), from 37 mmHg (95% 
CI 34–40 mmHg) to 31 mmHg (95% CI 29–33 mmHg; 
P = 0.01). In the chronic mountain sickness group, progres-
sive iron deficiency induced by venesection was associated 
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with an approximately 25% increase in pulmonary artery 
systolic pressure of 9 mmHg (95% CI 4–14 mmHg), from 
37 mmHg (95% CI 30–44 mmHg) to 46 mmHg (95% CI 
40–52 mmHg; P = 0.003). It was concluded that hypoxic 
pulmonary hypertension may be attenuated by iron supple-
mentation and exacerbated by iron depletion.52
The amount of blood donated by multitime donors is 
higher than by first-time blood donors, and both direct and 
indirect evidence42,43,52 suggests that there might be a level 
of tissue hypoxia in multitime donors because of a chronic 
state of anemia.
Anemia, erythropoietin, and VEGF
Increases in circulating levels of erythropoietin are propor-
tional to the levels of tissue hypoxia, which are influenced by 
hematocrit,53 and there are several papers reporting that ane-
mic patients have elevated levels of VEGF, which is a marker 
of tissue hypoxia.36,54 In a prospective study, plasma VEGF 
levels were measured prospectively in three groups of infants 
suspected of requiring red blood cell transfusions to find a 
vascular endothelial growth factor cutoff value indicative of 
tissue hypoxia. The three groups were acutely anemic (an 
episode of acute bleeding [hematocrit drop . 5%] per day), 
chronically anemic (hematocrit drop , 5% per day), and non-
transfused (hematocrit drop , 5% per day) but not meeting 
the clinical criteria for a transfusion. VEGF concentrations 
were lower in the acutely anemic infants than in the chroni-
cally anemic infants, but erythropoietin levels did not differ 
between these groups. The VEGF concentration was ,140 
pg/mL in all acutely anemic infants, and this was deemed to 
be the threshold level indicating sufficient tissue oxygenation 
in subsequent analysis. Interestingly, 30% of the chronically 
anemic infants had VEGF levels . 140 pg/mL.54
In patients with untreated locoregionally confined solid 
cancers of the head and neck, cervix, rectum, and lung, and 59 
additional patients without malignant disease (36 nonanemic 
patients without serious disease and 23 patients with renal 
anemia) it was shown that plasma levels of VEGF were 
16.2 ± 12.7 pg/mL in 36 nonanemic patients without malig-
nant disease, 49.2 ± 34.5 pg/mL in 49 patients with cancer 
(P , 0.001), and 89.9 ± 67.8 pg/mL in 23 patients with renal 
anemia (P = 0.001). VEGF levels in cancer patients were 
correlated significantly with hemoglobin levels. Patients with 
cancer had higher plasma levels of VEGF than patients 
without malignant disease if hemoglobin was $12 g/dL 
(33.1 ± 17.5 pg/mL versus 16.6 ± 13.0 pg/mL, P , 0.001) than 
if hemoglobin was 11.0–11.9 g/dL (56.1 ± 26.4 pg/mL versus 
18.5 ± 14.5 pg/mL, P = 0.038). If hemoglobin was ,11 g/dL, 
plasma VEGF levels were significantly elevated in patients 
with and without cancer (67.0 ± 47.5 pg/mL versus 88.9 ± 68.8 
pg/mL). A significant association between low hemoglobin 
levels and increased plasma levels of VEGF was confirmed. 
In patients with renal anemia, changes in hemoglobin under 
erythropoietin treatment were inversely correlated with 
changes in plasma VEGF levels, with   decreasing VEGF after 
an increase in hemoglobin (P = 0.01).36
Erythropoietin and VEGF interplay  
with retinal angiogenesis and 
retinopathy
It was recently shown that anemia of the newborn induces 
erythropoietin expression in the developing mouse retina.55 
Erythropoietin mRNA expression levels in the retina are 
greatly elevated during the hypoxia-induced proliferation 
phase of retinopathy in the mouse.56 A paper by Sato et al57 
confirms that the expression of ocular VEGF and erythro-
poietin are temporally linked in humans. In fact, expression 
of erythropoietin and VEGF mRNA is regulated by the same 
transcription factor, ie, HIF-1α, that binds to the cis-acting 
hypoxia-response element located in the 3′-flanking region 
of the human erythropoietin and VEGF gene.58 Like the 
proteins regulated by HIF-1α, HIF-1α activity can be pro-
tective at the right time and destructive at the wrong time. 
The right time of expression is when capillaries are present 
that are healthy enough to be protected by VEGF and eryth-
ropoietin. The wrong time is when ischemia is permanent, 
because the ischemic tissue is already expressing too much 
of these proteins.59
Takagi et al investigated the potential role of erythro-
poietin during retinal angiogenesis in proliferative diabetic 
retinopathy. The vitreous EPO level in patients with prolif-
erative diabetic retinopathy was significantly higher than 
that in nondiabetic patients. Erythropoietin and VEGF were 
both independently associated with proliferative diabetic 
retinopathy, and erythropoietin was more strongly associated 
with proliferative diabetic retinopathy than VEGF.   Blockade 
of erythropoietin inhibited retinal neovascularization in 
vivo, and inhibited endothelial cell proliferation response to 
proliferative diabetic retinopathy vitreous in vitro. Their data 
provide strong evidence that erythropoietin is a potent retinal 
angiogenic factor independent of VEGF, and is capable of 
stimulating ischemia-induced retinal angiogenesis in prolif-
erative diabetic retinopathy.60
Measurement of both erythropoietin and VEGF levels 
in the vitreous fluid of diabetic patients with proliferative 
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diabetic retinopathy has been shown to be much higher 
than that in patients without diabetes (464.0 mI/mL   versus 
36.5 mI/mL, P , 0.001). The median VEGF level in patients 
with retinopathy was also significantly higher than that in 
patients without diabetes (345.0 pg/mL versus 3.9 pg/mL, 
P , 0.001). Erythropoietin and VEGF were independently 
associated with proliferative diabetic retinopathy, and 
erythropoietin was more strongly associated with the pres-
ence of proliferative diabetic retinopathy than was VEGF. 
  Erythropoietin and VEGF gene expression levels are 
upregulated in the murine ischemic retina, and blockade of 
erythropoietin inhibits retinal neovascularization in vivo 
and endothelial cell proliferation in the vitreous of patients 
with diabetic retinopathy in vitro.61 Erythropoietin is a potent 
ischemia-induced angiogenic factor that acts independently 
of VEGF during retinal angiogenesis in proliferative diabetic 
retinopathy.
Chen et al investigated the inhibition of retinal eryth-
ropoietin mRNA expression with RNA interference as a 
potential strategy to suppress retinal neovascularization 
and to prevent proliferative retinopathy. They used a mouse 
model of oxygen-induced retinopathy. A small interference 
RNA (siRNA) targeting erythropoietin or control negative 
siRNA was injected intravitreally at postnatal days 12, 
14, and 15 during the hypoxic phase, and the effect on 
neovascularization was evaluated in retinal flat mounts at 
postnatal day 17. Retinal erythropoietin mRNA expression 
in the total retina was suppressed during the initial phase 
of vessel loss in retinopathy and was significantly elevated 
during the hypoxia-induced proliferative phase in all three 
neuronal layers in the retina, corresponding to an increased 
level of retinal hypoxia. EPOR mRNA expression levels 
also increased during the second neovascular phase, specifi-
cally in hypoxia-induced neovascular vessels. Intravitreous 
injection of erythropoietin siRNA effectively inhibited 
approximately 60% of retinal erythropoietin mRNA expres-
sion and considerably suppressed retinal neovascularization 
by approximately 40%.62
Evidence of retinal findings  
in anemic and hypoxic situations
In two prospective case series, it has been shown that 
retinal vascularization is affected by maternal anemia,63 
neonatal anemia,63 and the need for oxygen for more than 
48 hours.63,64 There are mounting case reports of ocular 
alterations in anemic or hypoxemia situations, such as reti-
nal vasculopathy,65 peripheral retinal neovascularization in 
Fanconi anemia,66 sickle cell hemoglobin C retinopathy,67 
or   idiopathic polypoidal choroidal vasculopathy and sickle 
cell retinopathy,68 branch retinal artery occlusion,69 retinal 
cotton wool spots and preretinal hemorrhages,70 unusual 
  morphological features of intraretinal and preretinal 
  neovascularization and of chorioretinal lesions in sickle 
cell retinopathy,71 peripheral retinal neovascularization in 
sarcoidosis and sickle cell anemia,72 and central retinal vein 
occlusion and nonarteritic ischemic optic neuropathy.70 
Blood et al described a retinopathy secondary to anemia from 
myeloid metaplasia in polycythemia vera.73 It is noteworthy 
that Fanconi anemia is characterized by high levels of serum 
erythropoietin as well as serum ferritin.74,75 A full review of 
numerous case reports of retinal alterations in anemia would 
be beyond the scope of this paper, and interested readers may 
refer to medical sources.
Relationship between 
erythropoietin and retinopathies
Diabetic retinopathy
The retinal angiogenic potential of erythropoietin in 
humans exacerbates proliferative diabetic retinopathy.76,77 
Diskin et al examined whether severity and progression of 
diabetic retinopathy could be accelerated by administra-
tion of rhEPO to patients with chronic renal failure. There 
was significantly greater deterioration of retinopathy after 
one year in the patients who had received erythropoietin 
(P = 0.004). The prevalence and severity of proliferative 
retinopathy appeared to have increased and was most closely 
associated with erythropoietin dosing.76 The erythropoietin 
vitreous concentration in the patients with proliferative 
diabetic retinopathy (512 [range 120–880] mU/mL) was 
significantly higher than in the patients with retinal detach-
ment, preretinal macular membranes, and macular holes 
(25.1 [range 5.2–201] mU/mL, P , 0.001).78 Also, the 
vitreous erythropoietin level was upregulated in eyes with 
proliferative vitreoretinopathy.79
Retinopathy of prematurity
Both early erythropoietin80 and late erythropoietin81,82 treat-
ment increases the risk of retinopathy of prematurity.  There 
is a consensus that rhEPO is a significant independent risk 
factor for the development of retinopathy of prematurity.57,80–87 
It has been suggested that the timing of rhEPO treatment 
during different stages of retinopathy is likely critical for 
determining its beneficial or destructive role in retinopathy 
of prematurity,88 and may explain the discrepancies seen in 
some studies.
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Oxygen-induced retinopathy and 
neovascularization
Chen et al studied the role of erythropoietin in a mouse model 
of retinopathy characterized by oxygen-induced vascular 
loss followed by hypoxia-induced pathological neovascu-
larization for the first time. Without treatment, local retinal 
erythropoietin levels were suppressed during the vessel loss 
phase. Administration of exogenous erythropoietin pre-
vented both vessel dropout and subsequent hypoxia-induced 
  neovascularization. Early use of erythropoietin also protected 
against hypoxia-induced retinal neuron apoptosis. In contrast, 
retinal erythropoietin mRNA levels were highly elevated 
during the retinopathy neovascular phase. Exogenous late 
erythropoietin treatment did not protect the retina, but rather 
enhanced pathological neovascularization. The early protec-
tive effect of erythropoietin occurred through both systemic 
retinal recruitment of proangiogenic bone marrow-derived 
progenitor cells and activation of prosurvival NF-κB via 
erythropoietin receptor activation on retinal vessels and 
  neurons. Early retinal erythropoietin suppression contributed 
to retinal vascular instability, and elevated erythropoietin 
levels during the proliferation stage contributed to neovas-
cularization and disease.89
It has been shown that the vitreous erythropoietin 
level is upregulated in eyes with rhegmatogenous retinal 
detachment.77–79,90 Anterior segment ischemia is a dreaded 
complication of retinal detachment. Conditions of relative 
hypoxia, such as sickle cell anemia91 and sickle cell hemoglo-
binopathy anemia,92 may precipitate vaso-occlusive phenom-
ena in retinal detachment. While tissue hypoxia secondary 
to the anemia in these patients with sickle cell anemia may 
play a role, it is also likely that direct vascular occlusion and 
endothelial damage from interaction with abnormal hemo-
globin tactoids also play a major role in retinopathy.
Hypothesis linking repeated blood  
donation to retinal angiogenesis
Previous studies have shown that maternal anemia in early 
pregnancy influences the pattern of placental vascularization,93 
and that maternal iron deficiency anemia may trigger a cas-
cade of pathophysiological processes, involving alterations 
in placental angiogenesis,94 chronic placental hypoxemia, 
and oxidative stress apoptosis.95 In adults with cyanotic 
congenital heart disease (n = 4, 27–47 years of age, mean 
systemic arterial oxygen saturation 77% [range 71%–81%] 
and mean hematocrit 64.5% [range 53.7%–69.5%]), retinal 
vascular tortuosity was increased, but no patient had ocular 
symptoms, and all eyes had good visual acuity. Increased 
retinal vascular tortuosity, which appears to be prevalent 
in adults with cyanotic congenital heart disease, is likely 
to be in response to hypoxemia and erythrocytosis because 
normalization of the retinal vascularity patterns after surgical 
relief of cyanosis resulted in resolution of hypoxemia and 
erythrocytosis.96
Shortt et al tested the hypothesis that chronic systemic 
hypoxia leads to angiogenesis in the adult retinal circulation 
in the absence of pre-existing vascular disease. Adult male 
Sprague-Dawley rats (n = 9) were exposed to a fraction of 
inspired oxygen of 0.10 for two weeks while control animals 
(n = 10) were exposed to room air. Chronic systemic hypoxia, 
in the absence of other pathological processes, caused angio-
genesis in the adult rat retina and provided an in vivo model 
for investigating this important process in the adult retina, 
in particular pathways specific to this tissue.97
To provide a possible mechanism by which repeated blood 
donation might enhance the risk of retinal neoangiogenesis 
and/or neovascularization, it might be helpful to mention the 
results of a study that was carried out to investigate the mecha-
nisms of adaptive response of the heart to long-term anemia 
induced by iron deficiency. Weanling Sprague-Dawley rats 
were fed an iron-deficient diet for 20 weeks to induce iron defi-
ciency anemia. The iron-deficient diet initially induced severe 
anemia, which resulted in left ventricular hypertrophy and dila-
tion with preserved systolic function associated with increased 
serum erythropoietin concentration. Cardiac signal transducer 
and activator of transcription 3 (STAT3) phosphorylation and 
VEGF gene expression increased by 12 weeks of iron deficiency 
anemia, causing angiogenesis in the heart. Thereafter, sustained 
iron deficiency anemia induced upregulation of cardiac HIF-1α 
gene expression and maintained upregulation of cardiac VEGF 
gene expression and cardiac angiogenesis. However, sustained 
iron deficiency anemia promoted cardiac fibrosis and lung 
congestion, with decreased serum erythropoietin concentration 
and cardiac STAT3 phosphorylation after 20 weeks of iron 
deficiency anemia compared with 12 weeks.47
STAT3 is an angiogenic factor and is expressed in the 
human retina. It has been shown that erythropoietin treatment 
may offer a unique dual-function strategy for neuroprotection 
and regeneration of retinal ganglion cells. Erythropoietin 
induced STAT3 phosphorylation in retinal ganglion cells, 
and inhibition of Jak2/STAT3 abolished erythropoietin-
induced growth. Erythropoietin-facilitated neuritogenesis 
was paralleled by upregulation of Bcl-X, a Bcl-2 homolog 
capable of promoting retinal ganglion cell regeneration. 
The PI3 K/Akt pathway was also involved in antiapoptotic 
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and regeneration-enhancing erythropoietin actions.98 Also, 
VEGF rapidly induces STAT3 tyrosine phosphorylation and 
nuclear translocation in retinal microvascular endothelial 
cells.99 STAT3 expression has been shown to be enhanced 
in hypoxia.100 Thus, it is possible that erythropoietin-induced 
and/or VEGF-induced STAT3 tyrosine phosphorylation is 
partly responsible for the retinal alterations in iron deficiency 
anemia and possibly in repeated blood donors.
Conclusion
Indirect evidence of enhanced erythropoietin production fol-
lowing repeated phlebotomy,20,23 single 400 mL phlebotomy,21 
and single 450 mL blood donation,22 together with findings 
of decreased hepcidin levels in superdonors,101 suggests 
decreased tissue oxygen saturation and oxygenated tissue 
hemoglobin values in repeated blood donors,42 decreased 
regional cerebral oxygen saturation (almost by half) after a 
single 450 mL blood donation,43 and enhanced VEGF pro-
duction in hypoxic situations,39 suggesting the possibility of 
existence of a chronic hypoxia and or hypoxemia in repeated 
blood donors, especially considering the fact that the primary 
stimulus for increasing erythropoietin synthesis is tissue 
hypoxia resulting from reduced blood oxygen availability.8,102 
Such a chronic hypoxia and/or hypoxemia status in repeated 
blood donors may induce HIF-1α expression, which in turn, 
might upregulate genes stimulating angiogenesis, resulting 
in the formation of a new vasculature.50,51
A linkage between repeat blood donation and retinal 
proliferation is possible, and further studies should be 
undertaken to see if changes in guidelines are required. This 
personal view does not negate the health effects of blood 
donation. Rather, it raises a question about ocular safety in 
multitime blood donors. Gathering and analyzing data on 
retinal findings from these people, either retrospectively or 
prospectively, might yield preliminary safety information, as 
well as those who donate blood for humanitarian reasons.
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